Siva Kumar Korada, Nagendra sastry Yarla, Anupam Bishayee, Gjumrakch Aliev, Aruna Lakshmi K., Arunasree M.K., Dhananjaya B.L. and Vijendra Mishra Pages 904 - 917 ( 14 )
Gastrointestinal (GI) disorders, especially microbial dysbiosis play role in several GI ailments such as irritable bowel syndrome, colorectal cancer, inflammatory bowel diseases, and antibiotic-associated diarrhoea. Role of inflammatory bowel disease (IBD) is multifactorial as it involves loss of maintaining intestinal epithelial barrier integrity, increased release of pro-inflammatory molecules, and microbial dysbiosis in gut microflora. Some specific pathogens also play a key role in the IBD development. The origin and causation are still in unfathomable condition and the exact root cause is unknown. Recently probiotic studies have been gaining importance because of their positive responses in their IBD experimental results. According to joint Food and Agricultural Organisation/World Health Organisation working group, probiotics are defined as live microorganisms which when administered in adequate amount confer health benefit on the host. These live beneficial microorganisms are considered helpful in improving gut colonization and perseverance thereby improves prophylactic effect. In the direction of IBD research, a number of studies are needed to standardize its methodology and its applicability on human usage. The particular review presents an overview of gut microflora and its impact on host health, types of IBD and existing therapies to treat this disorder, mechanism of several probiotic actions, role of probiotics in IBD prevention with their supporting evidences.
Probiotics, Gastrointestinal disorder, inflammatory bowel diseases, microbial dysbiosis, Ulcerative colitis.
Department of Biochemistry, Institute of Science, GITAM University, Vishakhapatnam, Andhra Pradesh, India., National Institute of Food Technology Entrepreneurship and Management (NIFTEM), Sonepat, Haryana, India.